Neurogastroenterology and Motility最新文献

{"title":"Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation.","authors":"Stefan Roos, Atti-La Dahlgren, Yu-Kang Mao, Anton Pallin, Andrew M Stanisz, Paul Forsythe, Wolfgang Kunze, Per M Hellström","doi":"10.1111/nmo.70012","DOIUrl":"https://doi.org/10.1111/nmo.70012","url":null,"abstract":"<p><strong>Background: </strong>Chronic constipation is a prevalent, burdensome gastrointestinal disorder whose etiology and pathophysiology remain poorly understood. Differences in the composition of the intestinal microbiota have been shown between constipated patients and healthy people. Data indicate that these microbial differences contribute to the disorder.</p><p><strong>Methods: </strong>Preclinical studies in mice examined the effects of Lactobacillus gasseri on intestinal motility ex vivo, the reversal of motility inhibition by μ-opioid receptor agonists ex vivo and in vivo in mice, and the effects on capsaicin-stimulated transient receptor potential vanilloid 1 (TRPV1) in Jurkat cells. Thereafter, a clinical study of 40 women with functional constipation was conducted to investigate the effects of Lactobacillus gasseri with a randomized parallel design. After 14 days of baseline recording, treatment with Lactobacillus gasseri or placebo was given over 28 days, with 14 days of follow-up. Outcomes with complete spontaneous bowel movements (CSBM), spontaneous bowel movements, emptying frequency, abdominal pain, time spent for defecation, Bristol stool form scale, use of rescue laxatives, and impact on sex life were investigated.</p><p><strong>Key results: </strong>In preclinical studies, Lactobacillus gasseri increased intestinal motility in an ex vivo model, reversed the motility inhibition caused by μ-opioid receptor agonist ex vivo and in vivo in mice, and counteracted capsaicin-stimulated activity of TRPV1 in Jurkat cells. In the clinical trial, Lactobacillus gasseri showed a significant reduction in abdominal pain, along with a correlation and tendency for an increased number of CSBM. Few adverse events were encountered.</p><p><strong>Conclusions and inferences: </strong>Treatment with Lactobacillus gasseri can alleviate pain sensations in functional constipation, possibly with an improved bowel-emptying function.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70012"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding Gastric Reflexes: The Role of Mechanosensitive Enteric Neurons in Stomach Motility.","authors":"Gemma Mazzuoli-Weber, Sophia Mayr, Kristin Elfers","doi":"10.1111/nmo.70011","DOIUrl":"https://doi.org/10.1111/nmo.70011","url":null,"abstract":"<p><p>This review focuses on mechanosensitive enteric neurons (MEN) in the guinea pig stomach and their roles in gastric motor reflex pathways. The guinea pig model is advantageous for studying gastric physiology, as its stomach structure and function closely resemble those of humans. Gastric motility involves distinct functional regions: the fundus and proximal corpus act as reservoirs, while the distal corpus and antrum handle food mixing and propulsion. Mechanosensitivity in both gastric cholinergic and nitrergic enteric neurons plays a critical role in adapting muscle activity in response to gastric content volume. These neurons enable reflex circuits involved in the accommodation reflex, with cholinergic excitatory and nitrergic inhibitory pathways promoting relaxation. This review summarizes the anatomical, functional, and neurochemical characteristics of MEN across gastric regions, their direct and indirect interactions with smooth muscle, and the role of distinct neurotransmitters in modulating gastric motility. The need for future studies on mechanosensitive pathways and involved neuronal receptors is highlighted to enhance our understanding, finally aiding therapeutic development.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70011"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of Anal Slow Waves and Ultraslow Waves in Patients With Constipation and Healthy Subjects.","authors":"Lulu Zhang, Yoav Mazor, Gillian Prott, Michael Jones, Allison Malcolm","doi":"10.1111/nmo.70006","DOIUrl":"https://doi.org/10.1111/nmo.70006","url":null,"abstract":"<p><strong>Background: </strong>Anal slow waves (SW) and ultraslow waves (USW) have been documented previously, yet their significance remains uncertain. Our aims were to characterize the prevalence and features of SW and USW in healthy subjects and patients with constipation and to correlate them with clinical features and anorectal physiological testing.</p><p><strong>Methods: </strong>Forty-three healthy female subjects and 83 female tertiary referral patients with constipation were included. High-resolution water-perfused manometry was performed. Retrospective blinded descriptive and quantitative analyses of manometric tracings were completed with a focus on SW and USW.</p><p><strong>Key results: </strong>SW were present in 58% of healthy subjects and 62% of constipated patients (p = 0.72) yet USW were seen almost exclusively in constipated patients (27% vs. 2% health; p < 0.0001). Frequencies and mean amplitudes of SW and USW were similar in both groups. Anal resting and squeeze pressures were higher in patients with SW compared to those without (p < 0.001, p = 0.004, respectively). Patients with USW had higher anal resting pressure and shorter duration of sustained squeeze compared to those without (p < 0.001 for both). There was a trend for less obstetric injury in constipated patients with USW compared to those without (23% vs. 48%; p = 0.05).</p><p><strong>Conclusions and interferences: </strong>While SW were common in both constipated and healthy subjects, USW were almost exclusively observed in constipated patients. Some correlations were observed with other anorectal physiology parameters such as high resting anal pressure with both SW and USW. Formal definitions for SW and USW are proposed. Further research into the clinical significance of these waves is warranted.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70006"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Pediatric Disorders of Gut-Brain Interaction on the Family: The Mediating Role of Child Somatic Symptoms.","authors":"Katlyn Garr, Cathleen Odar Stough, Meghan Flannery, Desale Yacob, Neetu Bali Puri, Ashley Kroon Van Diest","doi":"10.1111/nmo.70014","DOIUrl":"https://doi.org/10.1111/nmo.70014","url":null,"abstract":"<p><strong>Background: </strong>It is important to identify modifiable factors to reduce the negative impact of pediatric disorders of gut-brain interaction (DGBIs) on the family. The current study examined whether child somatic symptoms and caregiver mental health negatively influenced caregiver and family functioning.</p><p><strong>Methods: </strong>Participants were 84 children (8-17 years old) with DGBI symptoms and their caregivers presenting to a specialty DGBI clinic. Participants completed measures assessing demographics, child somatic symptoms, caregiver anxiety and depressive symptoms, and the impact of the child's illness on the family. Regression analyses examined if child somatic symptoms and caregiver and mental health were associated with family outcomes (i.e., Caregiver Health-Related Quality of Life [HRQoL], Family Functioning, Total Family Impact). Mediation analyses examined if child somatic symptoms mediated the association between caregiver mental health and Total Family Impact.</p><p><strong>Key results: </strong>Child somatic symptoms (self- and caregiver-report) were negatively related to Caregiver HRQoL, Family Functioning, and Total Family Impact (ps < 0.01). Caregiver anxiety was related to poorer Caregiver HRQoL (p < 0.001) and Total Family Impact (p = 0.01), while caregiver depression was negatively related to Family Functioning (p = 0.01). Self-report of child somatic symptoms partially mediated the association between caregiver anxiety and depressive symptoms and the Total Family Impact.</p><p><strong>Conclusions and inferences: </strong>Findings indicate that child somatic symptoms are one pathway by which caregiver mental health may amplify the impact of pediatric DGBIs on the family. This highlights the importance of screening for child somatic symptoms and caregiver mental health in pediatric DGBI treatment.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70014"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Dynamic Imaging Grade of Swallowing Toxicity for Amyotrophic Lateral Sclerosis.","authors":"Veena Kallambettu, Justine Dallal York, Terrie Vasilopolous, Katherine Hutcheson, Emily Plowman","doi":"10.1111/nmo.70008","DOIUrl":"https://doi.org/10.1111/nmo.70008","url":null,"abstract":"<p><strong>Introduction: </strong>Although dysphagia is prevalent in persons with amyotrophic lateral sclerosis (pALS) and is associated with morbidity and mortality, no validated outcomes currently exist for the gold standard videofluoroscopy (VF) exam. We therefore sought to psychometrically validate the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) scale in pALS.</p><p><strong>Methods: </strong>One hundred pALS attended a research evaluation and underwent a standardized VF and validated clinical outcomes of oral intake (FOIS), perceived swallowing impairment (EAT-10), and ALS disease progression (ALSFRS-Revised). Duplicate, independent, and blinded VF ratings were completed using the DIGEST and MBSImP scales. Weighted kappa, ANOVAs (Tukey's HSD, Welch's correction), and Chi-square analyses were performed to determine intra- and inter-rater reliability, criterion validity, and construct validity of the DIGEST scale for use in pALS.</p><p><strong>Results: </strong>The mean age was 64.4(SD = 10.4), 50% were male, and the average ALS duration was 28.2 months (SD = 22.2). Excellent intra-rater (kappa = 0.92-1.0) and inter-rater (kappa = 0.94) reliability were noted for DIGEST ratings. DIGEST grades significantly discriminated pharyngeal pathophysiology (MBSImP, F(3,96) = 24.7, p < 0.0001), perceived dysphagia (EAT-10, F(3,40) = 20.8, p < 0.0001), oral intake (FOIS, X²:25.4, df = 3, p < 0.0001), ALS bulbar disease progression (ALSFRS-bulbar, F(3,93) = 20.8, p < 0.0001) with main effects noted for all analyses. Post hoc pairwise comparisons noted differences across all DIGEST grades with the exception of DIGEST 2 versus 3 (moderate vs. severe dysphagia), p > 0.05.</p><p><strong>Conclusions: </strong>These data confirm that the DIGEST scale is a reliable and valid VF outcome for use in pALS to distinguish normal versus impaired swallowing and mild versus moderate or severe dysphagia for use in clinical practice and as a clinical trial endpoint marker.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70008"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Constipation Therapies on Severity of Gastroparesis and Constipation Symptoms in Relation to Gastric and Colonic Transit.","authors":"Brian C Surjanhata, Baharak Moshiree, Allen A Lee, Richard W McCallum, Irene Sarosiek, Linda A Nguyen, Michael I Schulman, John M Wo, Henry P Parkman, Braden Kuo, William L Hasler, Satish S C Rao","doi":"10.1111/nmo.70013","DOIUrl":"https://doi.org/10.1111/nmo.70013","url":null,"abstract":"<p><strong>Introduction: </strong>Studies demonstrate an overlap of constipation with gastroparesis and functional dyspepsia, but the impact of treatments that target constipation on improving upper gastrointestinal (UGI) symptoms is unexplored. We quantified the effects of constipation medication therapies on UGI and constipation symptom severity in subjects presenting with symptoms of gastroparesis.</p><p><strong>Methods: </strong>Fifty-six subjects with symptoms of gastroparesis underwent concurrent wireless motility capsule and gastric emptying scintigraphy and were recommended to receive either a new medication therapy for constipation or a change in constipation therapy based on investigator interpretation of test results. Gastroparesis Cardinal Symptom Index (GCSI), upper abdominal pain, and constipation scores were compared between baseline and 6 months. Data were compared between delayed or non-delayed gastric emptying and the presence or absence of slow colonic transit.</p><p><strong>Key results: </strong>Subjects with slow colonic transit had improvements in GCSI (p = 0.007) and constipation scores (p = 0.004) after treatment with a new or changed constipation medication, with the delayed emptying subgroup driving GCSI improvements (p = 0.004). Reductions in nausea/vomiting (p = 0.02) and early satiety/fullness subscores (p = 0.002) with trends to improved bloating/distention subscores (p = 0.06) were observed in this subgroup, but upper abdominal pain was unchanged. Subjects with normal colonic transit showed no improvement in GCSI scores regardless of gastric emptying status (p > 0.05).</p><p><strong>Conclusions and inferences: </strong>Identifying and treating delayed colonic transit in gastroparetic (delayed gastric emptying) subjects improves global UGI symptoms as well as selected individual symptoms. Evaluation of whole gut motility as well as recognizing and managing extragastric delay may promote improved outcomes in these patients.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT02022826.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70013"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Could the Therapeutic Effect of Physical Activity on Irritable Bowel Syndrome Be Mediated Through Changes to the Gut Microbiome? A Narrative and Hypothesis Generating Review.","authors":"Hannah B Lindsell, Neil C Williams, Daniele Magistro, Maura Corsetti, Gemma E Walton, Kirsty A Hunter","doi":"10.1111/nmo.70004","DOIUrl":"https://doi.org/10.1111/nmo.70004","url":null,"abstract":"<p><strong>Background: </strong>Irritable bowel syndrome (IBS) is one of the most prevalent gastrointestinal (GI) disorders worldwide. Defined as a disorder of gut-brain interaction, its pathophysiology is still not completely clear. Consequently, current treatments primarily target symptoms rather than addressing the cause of the condition. The gut microbiome is increasingly acknowledged as central to IBS pathophysiology and, thus, may have therapeutic potential. Several national treatment guidelines recommend increasing physical activity for IBS management.</p><p><strong>Aims: </strong>This review summarises the evidence about the relationship between physical activity, IBS symptoms, and the gut microbiome, investigating the hypothesis that physical activity's therapeutic effects on IBS may be explained via modulation of the gut microbiome.</p><p><strong>Results: </strong>This review revealed that routine exercise was associated with a 15%-66% reduction in symptom severity and up to 41% enhanced QoL in IBS participants, and modulates the gut microbiome in healthy controls.</p><p><strong>Discussion: </strong>This review generates the hypothesis that routine physical activity may favorably alter gut microbiome composition in IBS to improve IBS symptomology. While a plausible hypothesis, research needs to confirm whether gut microbiome modulation is involved in physical activity associated IBS symptom relief.</p><p><strong>Conclusion: </strong>Furthermore, the establishment of the most effective mode, duration, and intensity of physical activity for each sex and IBS-subtype is needed, with patient input during this process crucial to successfully translate science into practice.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70004"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Antidepressants in Patients With Depression Is Associated With Gastroesophageal Reflux Disease and Disease Severity.","authors":"Sherif Saleh, Ronnie Fass","doi":"10.1111/nmo.70010","DOIUrl":"https://doi.org/10.1111/nmo.70010","url":null,"abstract":"<p><strong>Introduction: </strong>A few studies have demonstrated an association between gastroesophageal reflux disease (GERD) and depression, with some reporting that antidepressants may affect lower esophageal sphincter tone, thus exacerbating reflux. Here, we study the impact of antidepressants in patients with depression on GERD and its complications.</p><p><strong>Methods: </strong>The TriNetX electronic health records network, which involves 70 healthcare organizations in the United States was utilized for this study. Data from patients between January 2015 and January 2025 was used. Patients with depression on tricyclic antidepressant (TCA) only, on selective serotonin reuptake inhibitors (SSRI) only, or on serotonin and norepinephrine reuptake inhibitors (SNRI) only were evaluated. The prevalence of developing a new diagnosis of GERD, erosive esophagitis (EE), esophageal stricture, or Barrett's esophagus (BE) was assessed in each group and compared to a control group of patients with depression on no antidepressants. Adjusted odds ratios (aOR) were used after a 1:1 propensity score matching for age, obesity, male sex, Caucasian race, alcohol use, and tobacco use between comparison groups. A sensitivity analysis evaluating the odds of developing GERD, EE, BE, or esophageal stricture within 1 month, 6 months, 1 year, 3 years, 5 years, and 10 years after initiation of antidepressant was also conducted.</p><p><strong>Results: </strong>A total of 2,775,955 patients with depression started on an antidepressant. The use of TCA was associated with increased odds of developing GERD (aOR = 1.52, p < 0.01), EE (aOR = 1.47, p < 0.01), and esophageal stricture (aOR = 2.29, p < 0.01). There was no significance with BE (aOR = 1.18, p = 0.226). The use of SSRI was associated with increased odds of GERD (aOR = 1.48, p < 0.01), EE (aOR = 1.46, p < 0.01), BE (aOR = 1.21, p < 0.01), and esophageal stricture (aOR = 1.35, p < 0.01). The use of SNRI was associated with increased risk of GERD (OR = 1.53, p < 0.01), EE (OR = 1.53, p < 0.01), BE (OR = 1.30, p < 0.01), and esophageal stricture (OR = 1.60, p < 0.01).</p><p><strong>Conclusion: </strong>There is an increased association in developing GERD, EE, BE, and esophageal stricture with TCA, SSRI, and SNRI use. This association increased with prolonged use of medication over 10 years. Further prospective studies are needed to confirm our findings.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70010"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment principles in adults and development of patient-reported outcomes in cyclic vomiting syndrome.","authors":"Yaozhu J Chen, Milan Patel, Thangam Venkatesan","doi":"10.1111/nmo.14910","DOIUrl":"10.1111/nmo.14910","url":null,"abstract":"<p><strong>Background: </strong>Cyclic vomiting syndrome is a chronic disorder of gut-brain interaction that is present in both adults and children. It is characterized by severe nausea, vomiting, abdominal pain, and several non-GI symptoms. It is also associated with several comorbid conditions such as anxiety and depression, which affect overall health care outcomes.</p><p><strong>Methods: </strong>This article delineates treatment principles, encompassing both abortive interventions and prophylactic regimens currently recommended for CVS. However, it underscores a critical concern: the absence of FDA-approved medications for CVS treatment, with existing therapies relying on retrospective and open-labeled trials.</p><p><strong>Key results: </strong>This article emphasizes the pressing need for the development of CVS-specific outcome assessment tools to facilitate more accurate evaluation and robust data collection for the future studies. In exploring this deficiency, the manuscript also presents the up-to-date data and development that enhances our comprehension of patient-centric concepts, and the challenges faced in creating CVS-specific tools, and presents a roadmap for their development. Addressing this gap is crucial for advancing our understanding of CVS and optimizing patient care.</p><p><strong>Conclusions and inferences: </strong>This elucidates the current state of CVS management but also advocates for a future where tailored tools enhance our ability to measure and improve the outcomes for individuals with this debilitating disorder.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e14910"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based review and frontiers of migraine therapy.","authors":"Kaitlin A Greene, Amy A Gelfand, Larry Charleston","doi":"10.1111/nmo.14899","DOIUrl":"10.1111/nmo.14899","url":null,"abstract":"<p><strong>Background: </strong>Cyclic vomiting syndrome (CVS) is identified as one of the \"episodic syndromes that may be associated with migraine,\" along with benign paroxysmal torticollis, benign paroxysmal vertigo, and abdominal migraine. It has been proposed that CVS and migraine may share pathophysiologic mechanisms of hypothalamic activation and altered dopaminergic signaling, and impaired sensorimotor intrinsic connectivity. The past decade has brought groundbreaking advances in the treatment of migraine and other headache disorders. While many of these therapies have yet to be studied in episodic syndromes associated with migraine including CVS and abdominal migraine, the potential shared pathophysiology among these conditions suggests that use of migraine-specific treatments may have a beneficial role even in those for whom headache is not the primary symptom.</p><p><strong>Purpose: </strong>This manuscript highlights newer therapies in migraine. Calcitonin gene-related peptide (CGRP) and its relation to migraine pathophysiology and the therapies that target the CGRP pathway, as well as a 5HT1F receptor agonist and neuromodulation devices used to treat migraine are briefly discussed as they may potentially prove to be useful in the future treatment of CVS.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e14899"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}